-
1دورية أكاديمية
المؤلفون: Gangadhar, Tara C, Hwu, Wen-Jen, Postow, Michael A, Hamid, Omid, Daud, Adil, Dronca, Roxana, Joseph, Richard, O’Day, Steven J, Hodi, FS, Pavlick, Anna C, Kluger, Harriet, Oxborough, Romina P, Yang, Aiming, Gazdoiu, Mihaela, Kush, Debra A, Ebbinghaus, Scot, Salama, April KS
المصدر: Journal of Immunotherapy. 40(9)
مصطلحات موضوعية: Clinical Research, Cancer, Clinical Trials and Supportive Activities, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Clinical Trials as Topic, Drug Resistance, Neoplasm, Drug-Related Side Effects and Adverse Reactions, Exanthema, Fatigue, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Treatment Outcome, United States, Young Adult, expanded access program, immunotherapy, melanoma, PD-1, pembrolizumab, Immunology
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/60z5g7xzTest
-
2دورية أكاديمية
المؤلفون: Ribas, Antoni, Puzanov, Igor, Dummer, Reinhard, Schadendorf, Dirk, Hamid, Omid, Robert, Caroline, Hodi, F Stephen, Schachter, Jacob, Pavlick, Anna C, Lewis, Karl D, Cranmer, Lee D, Blank, Christian U, O'Day, Steven J, Ascierto, Paolo A, Salama, April KS, Margolin, Kim A, Loquai, Carmen, Eigentler, Thomas K, Gangadhar, Tara C, Carlino, Matteo S, Agarwala, Sanjiv S, Moschos, Stergios J, Sosman, Jeffrey A, Goldinger, Simone M, Shapira-Frommer, Ronnie, Gonzalez, Rene, Kirkwood, John M, Wolchok, Jedd D, Eggermont, Alexander, Li, Xiaoyun Nicole, Zhou, Wei, Zernhelt, Adriane M, Lis, Joy, Ebbinghaus, Scot, Kang, S Peter, Daud, Adil
المصدر: The Lancet Oncology. 16(8)
مصطلحات موضوعية: Clinical Trials and Supportive Activities, Cancer, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Humans, Intention to Treat Analysis, Ipilimumab, Kaplan-Meier Estimate, Male, Melanoma, Middle Aged, Skin Neoplasms, Time Factors, Treatment Outcome, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis
وصف الملف: application/pdf
الوصول الحر: https://escholarship.org/uc/item/8j23r3pnTest
-
3دورية أكاديمية
المؤلفون: Gangadhar, Tara C, Hwu, Wen-Jen, Postow, Michael A, Hamid, Omid, Daud, Adil, Dronca, Roxana, Joseph, Richard, O'Day, Steven J, Hodi, F S, Pavlick, Anna C, Kluger, Harriet, Oxborough, Romina P, Yang, Aiming, Gazdoiu, Mihaela, Kush, Debra A, Ebbinghaus, Scot, Salama, April K S
المصدر: Articles, Abstracts, and Reports
مصطلحات موضوعية: Adolescent, Adult, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Clinical Trials as Topic, Drug Resistance, Neoplasm, Drug-Related Side Effects and Adverse Reactions, Exanthema, Fatigue, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Treatment Outcome, United States, Young Adult, Oncology
وصف الملف: application/pdf
العلاقة: https://digitalcommons.psjhealth.org/publications/452Test; https://digitalcommons.psjhealth.org/context/publications/article/1449/viewcontent/cji_40_334.pdfTest
-
4دورية أكاديمية
المؤلفون: Hamid, Omid1 ohamid@theangelesclinic.org, Puzanov, Igor2, Dummer, Reinhard3, Schachter, Jacob4, Daud, Adil5, Schadendorf, Dirk6, Blank, Christian7, Cranmer, Lee D.8, Robert, Caroline9, Pavlick, Anna C.10, Gonzalez, Rene11, Hodi, F. Stephen12, Ascierto, Paolo A.13, Salama, April K.S.14, Margolin, Kim A.15, Gangadhar, Tara C.16, Wei, Ziwen17, Ebbinghaus, Scot17, Ibrahim, Nageatte17, Ribas, Antoni18
المصدر: European Journal of Cancer. Nov2017, Vol. 86, p37-45. 9p.
مصطلحات موضوعية: *THERAPEUTIC use of monoclonal antibodies, *CANCER chemotherapy, *COMPARATIVE studies, *CONFIDENCE intervals, *CROSSOVER trials, *DRUG resistance, *DRUG side effects, *MELANOMA, *MONOCLONAL antibodies, *STATISTICAL sampling, *SKIN tumors, *SURVIVAL analysis (Biometry), *RANDOMIZED controlled trials, *TREATMENT effectiveness, *PROPORTIONAL hazards models, *IPILIMUMAB, *DESCRIPTIVE statistics